Evotec SE received a share price boost on 24 September after the German biotech announced its latest multi-year drug discovery collaboration, this time with Japan-based with Takeda Pharmaceutical Co. Ltd., under which the duo will aim to develop at least five drug candidates by leveraging Evotec's drug discovery platform.
Their therapeutic focus will be on oncology, gastroenterology, neuroscience and rare diseases.





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
